PhotoPharmics has formed a commercial advisory board (CAB) to help guide the market launch of Celeste, its US Food and Drug Administration (FDA) Breakthrough device for Parkinson’s disease.
The board unites leading figures in neurology, movement disorders and pharmaceutical and medtech commercialisation to support the company as it prepares the device for regulatory submission and entry into the market.
Celeste is a phototherapy device designed to address Parkinson’s symptoms through a non-invasive approach. The technology has the potential to fill a critical gap in care by working alongside existing drug and surgical options.
Chaired by Jordan Dubow, a fellowship-trained movement disorders neurologist with more than 20 years of clinical and industry leadership, the CAB brings together a multidisciplinary group spanning clinical practice, regulatory strategy, health economics and global product launches. Members include Jill Giordano Farmer, Drew Falconer, Robert A Hauser, Rajesh Pahwa, Philip Cyr and Michael Soileau.
“Celeste has the potential to fill a critical gap in Parkinson’s care by addressing symptoms in a completely new way,” said Dubow. “Our role on the Commercial Advisory Board is to ensure that people with Parkinson’s, know the therapeutic device is available and have access to the device when FDA grants market authorization.”
Kent Savage, CEO of PhotoPharmics, said: “We’re entering a decisive stage where market readiness is as critical as clinical success. This board brings unmatched expertise to help us navigate pricing, access and adoption strategies that will get Celeste to the people who need it most.”
He added: “The formation of this board ensures our commercialisation pathway is informed by leaders who understand the science, the market and the patients whom we aim to serve.”
Founded in Utah in the US, PhotoPharmics is a clinical-stage medical device company developing light-based therapies for neurodegenerative conditions.